Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide interaction study with morphine and edoxaban in prostate cancer
2022-001410-20Phase 4Active
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of enzalutamide, edoxaban and morphine in prostate cancer (PCa) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Change in edoxaban exposure and Change in M4 exposure. Started Sep 2022; status: active.
02
Drugs
enzalutamideedoxabanmorphine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-001410-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001410-20.